![]() |
|
|
Department of Food Science and Human Nutrition and the Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801
3To whom correspondence should be addressed. E-mail: jwerdman{at}uiuc.edu.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: tomato lycopene prostate cancer cardiovascular disease
Annually, the average American consumes 17.9 pounds of fresh tomatoes (Lycopersicon esculentum) and 68.7 pounds of processed tomato products, as shown in Table 1 (1,2). Onions, head lettuce, and potatoes are the only fresh vegetables consumed more frequently than tomatoes in America, whereas tomatoes are by far the most frequently consumed canned vegetable (1,2). The Economic Research Service of the USDA estimates that 35% of raw tomatoes are processed into sauces, 18% into tomato paste, 17% for canned tomatoes, 15% into juices, and 15% into catsup (2). Interestingly, teenage boys (ages 1219 y) have the highest per capita consumption of catsup, with fresh tomato and tomato juice consumption rising with increased age in both men and women (2). Many tomato products are good sources of potassium, folate, and the vitamins A, C, and E, as demonstrated in Table 2 (3). Tomato products contain similar amounts of potassium and folate compared with other popular vegetables, but tomato products are a superior source of alpha-tocopherol and vitamin C (3). In comparison with the other regularly consumed vegetables, only carrots are a better dietary source of vitamin A than tomato-based foods.
|
|
288 µg/g) and other food sources of lycopene include fresh watermelon (
45 µg/g) and pink grapefruit (
14 µg/g) (6,7).
|
Tomatoes, lycopene, and prostate cancer risk
Epidemiological evidence.
Several epidemiological studies have reported an inverse relation between consumption of tomatoes and/or its major carotenoid lycopene, and reduced prostate cancer risk. Using plasma samples from men enrolled in the Physicians Health Study, a randomized and placebo-controlled trial of aspirin and ß-carotene, lycopene was found to be the only antioxidant at significantly lower levels in prostate cancer cases than in the matched controls (P = 0.04) (13). This inverse association was particularly evident for aggressive types of prostate cancer and for men not taking a ß-carotene supplement. A case-control study was performed to examine plasma carotenoids and the risk for prostate cancer, using a standard epidemiological questionnaire and serum carotenoid analysis via HPLC in 65 prostate cancer patients and 132 cancer-free controls (14). An 83% reduction in prostate cancer risk was observed in the group with the highest plasma lycopene concentration (0.40 µm/L) in comparison with the lowest lycopene group (0.18 µm/L) (14). In the Health Professionals Follow-Up Study, similar results were found, where an intake of
2 servings a week of tomato products resulted in a lower risk of prostate cancer (15). This particular study examined 51,529 male heath professionals between 40 and 75 y of age and evaluated lycopene and tomato product intakes and established that a greater risk reduction for prostate cancer occurred with tomato sauce [relative risk (RR) = 0.77 for 2+ servings/wk vs. <1 serving/mo; 95% CI: 0.660.90; Ptrend < 0.001] than with lycopene intake alone (RR = 0.84 for high vs. low quintiles; 95% CI: 0.730.96; Ptrend = 0.003) (15). A nested case-control study from the Health Professionals Follow-Up Study cohort further examined the association between plasma carotenoids and prostate cancer risk (16). By matching 450 cases with 450 controls, it was determined that there was a significant inverse relation between a higher concentration of serum lycopene and a lower risk of prostate cancer. This finding was restricted to older men and those without a family history of prostate cancer. The authors speculated that these findings indicate that tomatoes have the ability to protect against sporadic prostate cancer better than familial prostate cancer.
A recent meta-analysis searched both MEDLINE and EMBASE for relevant tomato and prostate cancer papers and 11 case-control studies and 10 cohort studies were chosen for analysis (17). At the time of this meta-analysis, the case-control study described above (16) was not yet published and therefore was not included. This meta-analysis found that, compared with infrequent consumers of raw tomatoes, the RR for prostate cancer in the highest quartile of intake was 0.89 (95% CI: 0.801.00), and for those consuming cooked tomato products, the RR was 0.81 (95% CI: 0.710.92) (17). The authors noted that the effect seen was modest even with high levels of tomato intake. Overall, epidemiological evidence supports further investigation of the relation between tomato product consumption and reduced risk for developing prostate cancer. Animal studies would allow scientists to elucidate the possible mechanisms of action, as well as the dose and the form of tomatoes that might provide optimum cancer risk reduction, before more expensive and time-consuming clinical trials.
Experimental evidence. There are several established animal models that can be used to study prostate cancer initiation, promotion, and progression, some of which are appropriate for dietary intervention studies. One such model, is the N-methyl-N-nitrosourea (NMU) and testosterone-induced prostate cancer model, developed by Bosland (18,19). This model was used by our laboratory to examine the effects of tomato or lycopene consumption on prostate cancer development. In this study, rats were fed an AIN-93G based diet containing 10% tomato powder or 0.025% lycopene. Feeding tomato powder resulted in significantly longer survival due to fewer prostate cancer deaths than rats given the control diet (hazard ratio = 0.74; 95% CI: 0.590.93; P = 0.009) (20). The lycopene-containing diet (hazard ratio = 0.91; 95% CI: 0.611.35; P = 0.630) resulted in a nonsignificant reduction in survival from prostate cancer, suggesting that there may be phytochemicals, in addition to lycopene, contained in tomatoes, which may aid in cancer prevention.
The Dunning R-3327H transplantable tumor model examines the later stages of cancer in prostate cells placed subcutaneously in Copenhagen male rats (21,22). Our laboratory examined effects of diets containing tomato powder, lycopene, broccoli powder, and a combination of tomato plus broccoli powder, to determine which dietary additions were most effective in decreasing prostate tumor growth. Results from the pilot study suggest that diets containing broccoli, tomato, lycopene, and a combination of tomato and broccoli powders can all reduce the Dunning R-3327H prostate tumor growth rate (23). Further animal trials will be performed in the coming year to more clearly examine these dietary interventions, as well as to evaluate possible additive effects between broccoli and tomato powder. Possible mechanisms of action will also be tested to determine how these dietary interventions might reduce tumor growth.
A recently published study examined the effects of lycopene and/or vitamin E, 2 components of tomatoes, on prostate tumor growth using the Dunning MatLyLu rat model (24). In this model, rapidly growing tumor cells are injected directly into the ventral prostate of rats. Whereas no dietary interventions decreased tumor size, lycopene, vitamin E, and their combination all increased the fractional area of tumor tissue, which was necrotic, compared with the untreated and vehicle-treated animals. Microarray analysis of tumor tissues showed a reduction in androgen signaling via vitamin E, whereas lycopene acted by downregulating 5-alpha reductase 1, insulin-like growth factor-1, and IL-6 expression.
It is notable that studies with 3 rat models of prostate cancer provided encouraging results. Clearly, more animal model research needs to be performed. At this time, the animal work, in combination with the epidemiology, supports the need for clinical trials in human subjects, focused upon diets containing tomatoes, tomato-based foods, and tomato phytochemicals.
Tomatoes, lycopene, and CVD risk
Several epidemiological studies have linked elevated plasma lycopene concentration with a lower risk for developing CVD (25). For example, the Kuopio Ischemic Heart Disease Risk Factor Study examined the relation between serum antioxidants and intima-mediated thickness of the common carotid artery (CCA-IMT), a marker related to the risk of having an acute coronary event. They reported that lower levels of plasma lycopene were seen in men who had a coronary event compared with men who did not (26,27). In addition, a higher concentration of serum lycopene was inversely correlated with a decrease in the mean and maximal CCA-IMT (P for linear trend < 0.001) with low lycopene, resulting in an 18% increase in CCA-IMT (27). The Eupopean Multicenter Case-Control Study on Antioxidants, Myocardial Infarction and Breast Cancer Study, better known as the EURAMIC Study, is another case-control study that examined the correlation between adipose lycopene concentration and CVD risk. In that study, adipose samples were analyzed for carotenoid content, because this tissue is considered a long-term storage depot for carotenoids. A higher lycopene concentration was found to be independently protective against CVD. Specifically, the odds ratio for lycopenes protective effect was 0.52 when contrasting the 10th and 90th percentiles of adipose lycopene concentrations (28).
Since 1984, CVD has caused more deaths in females than males, claiming one death per minute, accounting for half a million women a year (12). The Womens Health Study is a continuing randomized, double-blind, placebo controlled 2 x 2 factorial study examining the effect of vitamin E and aspirin on the prevention of CVD and cancer in women (29,30). The participants filled out FFQs and women in the first quintile of tomato consumption (<1.5 servings a week) were compared with those eating 1.5 to <4, 4 to <7, 7 to <10, or
10 servings a week. The RRs of CVD with tomato intake were 1.02, 1.04, 0.68, and 0.71, respectively (P for trend = 0.029). It was also reported that a decreased risk for developing CVD was more strongly associated with higher tomato intake than with lycopene intake (29). Blood samples were analyzed for lycopene concentration, and the women in the upper 3 quartiles of plasma lycopene were found to have a significant, multivariate, 50% risk reduction for developing CVD compared with those in the lowest quartile (95% CI: 0.330.82, P = 0.005) (30). This epidemiological work suggests that examination of the effects of tomato and tomato phytochemical consumption on CVD development in animal models may provide some interesting data to help establish the role of tomatoes in a cardioprotective diet.
Tomato bioactive components and modes of action
Tomatoes contain many bioactive components, including those that act as antioxidants, such as the vitamins C and E, and many carotenoids. As the main carotenoid in tomatoes, lycopene is often assumed to be responsible for the positive health effects seen with increased tomato intake. Particularly, lycopene is the most efficient carotenoid at scavenging singlet oxygen and reactive oxygen species (31,32). The antioxidant effect of lycopene is potentially beneficial in disease prevention for both CVD and prostate cancer. In regard to CVD, lycopene and tomatoes could possibly reduce the disease development by reducing inflammation, inhibiting cholesterol synthesis, or improving immune function (25).
The proposed mechanisms of action of lycopene in prostate cancer prevention includes inhibition of proliferation, anti-androgen and antigrowth factor effects (33,34). Foods rich in lycopene have been found to decrease endogenous levels of DNA strand breaks in human lymphocytes (35). In an attempt to understand mechanisms that might explain the inverse relation between dietary intakes of lycopene/tomato and prostate cancer risk, 15 men were given either placebo or Lyc-O-Mato, containing 15 mg of lycopene, 2.5 mg phytoene and phytofluene, and other minor carotenoids, twice a day for 3 wk before radical prostatectomy (36). Researchers ascertained that the lycopene supplemented group had less cancer at the surgical margins and in extraprostatic tissues, smaller tumors, and an 18% reduction in prostate specific antigen (PSA) levels, whereas the control groups PSA levels increased by 14%. Lycopene treatment was also found to increase expression of connexin 43 in cancerous prostate tissue. Connexin 43 is a recognized tumor suppressor gene, which can increase gap junction communication and therefore suppress overgrowth of cells (36).
In a second small clinical trial, 32 prostate cancer patients consumed tomato-saucebased pasta dishes daily, containing 30 mg lycopene, for 3 wk before their scheduled radical prostatectomy (37). Although there was no control group, the tomato-product consumption resulted in a decrease in serum PSA levels from 10.9 to 8.7 µg/L (P = < 0.001). Leukocyte oxidative DNA damage was statistically lower after regular tomato consumption than before the dietary intervention. In addition, prostate tissue also showed a reduced amount of oxidative DNA damage in men who were treated compared with those who were randomly selected.
| CONCLUSIONS |
|---|
|
|
|---|
| FOOTNOTES |
|---|
2 Supported in part by USDA/IFAFS grant #00521029695 and AICR grant #01B061. ![]()
4 Abbreviations used: CCA-IMT, common carotid artery; CVD, cardiovascular disease; NMU, N-methyl-N-nitrosourea; PSA, prostate specific antigen. ![]()
| LITERATURE CITED |
|---|
|
|
|---|
1. Agriculture Statistics (2003) Chapter IV: Statistics of Vegetables and Melons. USDA National Agricultural Statistic Services, 2003 2003 United States Government Printing Office Washington, DC.
2. Lucier, G., Lin, B., Allshouse, J. & Kantor, L. (2002) Factors Affecting Tomato Consumption in the United States. Vegetables and Specialities/VGS-282/November 2000 2002 Economic Research Service USDA. http://www.ers.usda.gov/briefing/consumption/gallery/tomatoconsumption.pdf [accessed June 15, 2004].
3. USDA Nutrient Data Bank [Online]. http://www.nal.usda.gov/ [accessed June 2004].
4. Tonucci, L., Holden, J., Beecher, G., Khackik, F., Davis, C. & Mulokozi, G. (1995) Carotenoid content of thermally processed tomato-based food products. J. Agric. Food Chem. 43:579-586.
5. Stewart, A., Bozonnet, S., Mullen, W., Jenkins, G., Lean, M. & Crozier, A. (2000) Occurrence of flavonols in tomatoes and tomato-based products. J. Agric. Food Chem. 48:2663-2669.[Medline]
6. USDA National Nutrient Database for Standard Reference, Release 161 2004 Lycopene Content of Selected Foods, Per Common Measure, Sorted by Nutrient Content. http://www.nal.usda.gov/fnic/foodcomp [accessed July 2004].
7. Levy, J. & Sharoni, Y. (2004) The functions of tomato lycopene and its role in human health. Herbal Gram. 62:49-56.
8. Wilkinson, S. & Chodak, G. W. (2003) Critical review of complementary therapies for prostate cancer. J. Clin. Oncol. 21:2199-2110.
9. Cohen, L. A. (2002) Nutrition and prostate cancer: a review. Ann. N.Y. Acad. Sci. 963:148-155.
10. Cancer Facts and Figures (2005) The American Cancer Society 2005 http://www.cancer.org/docroot/stt/stt_o.dsp [accessed March 2005].
11. Krauss, R. M., Eckel, R. H., Howard, B., Lawrence, J., Appel, L. J., Daniels, S. R., Deckelbaum, R. J., Erdman, J. W., Jr & Kris-Etherton, P., et al (2000) AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102:2284-2299.
12. Heart Disease and Stroke Statistics. Update. American Heart Association http://www.americanheart.org/downloadable/heart/1105390918119HOSStats2005update.pdf [accessed March 2005].
13. Gann, P., Ma, J., Giovannucci, E., Willett, W., Sacks, F., Hennekens, C. & Stampfer, M. (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 59:1225-1230.
14. Lu, Q., Hung, J., Heber, D., Go, V., Reuter, V., Crordon-Cardo, C., Scher, H., Marshall, J. & Zhang, Z. (2001) Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 10:749-756.
15. Giovannucci, E., Rimm, E., Liu, Y., Stampfer, M. & Willett, W. (2002) A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst. 94:391-398.
16. Wu, K., Erdman, J. W., Jr, Schwartz, S. J., Platz, E. A., Leitzmann, M., Clinton, S. K., DeGroff, V., Willett, W. C. & Giovannucci, E. (2004) Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol. Biomarkers Prev. 13:260-269.
17. Etminan, M., Takkouche, B. & Caamano-Asorna, F. (2004) The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol. Biomarkers Prev. 13:340-345.
18. Bosland, M. C. (1992) Animal models for the study of prostate carcinogenesis. J. Cell Biochem. Suppl. 16H:89-98.[Medline]
19. Bosland, M. C., Prinsen, M. K. & Kroes, R. (1983) Adenocarcinomas of the prostate induced by N-nitroso-N-methulurea in rats pretreated with cyproterone acetate and testosterone. Cancer Lett. 18:69-78.[Medline]
20. Boileau, T. W., Liao, Z., Kim, S., Lemeshow, S., Erdman, J. W., Jr & Clinton, S. K. (2003) Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J. Natl. Cancer Inst. 95:1578-1586.
21. Tennant, T. R., Kim, H., Sokoloff, M. & Rinker-Schaeffer, C. W. (2000) The Dunning Model. Prostate 43:295-302.[Medline]
22. Isaacs, J. T., Isaacs, W. B., Feitz, W.F.J. & Scheres, J. (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9:261-281.[Medline]
23. Canene-Adams, K., Clinton, S. K., King, J. L., Lindshield, B. L., Wharton, C., Jeffery, E. & Erdman, J. W., Jr (2004) The growth of the Dunning R-3327-H transplantable prostate adenocarcinoma in rats fed diets containing tomato, broccoli, lycopene, or receiving finasteride treatment. FASEB J. 18:A886 (591.4).
24. Siler, U., Barella, L., Spitzer, V., Schnorr, J., Lein, M., Goralczyk, R. & Wertz, K. (2004) Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J. 18:1019-1021.
25. Petr, L. & Erdman, J. W. (2005) Lycopene and risk of cardiovascular disease. Packer, L. Obermueller-Jevic, U. Kramer, K. Sies, H. eds. Carotenoids and Retinoids: Biological Actions and Human Health 2005:204-217 AOCS Press Champaign, IL. .
26. Rissanen, T., Voutilainen, S., Nyyssonen, K. & Salonon, J. (2002) Lycopene, atherosclerosis, and coronary heart disease. Exp. Biol. Med. 227:900-907.
27. Rissanen, T., Voutilainen, S., Nyyssonen, K., Salonon, J., Kaplan, G. & Salonen, J. (2003) Serum lycopene concentration and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am. J. Clin. Nutr. 77:133-138.
28. Kohlmeier, L., Kark, J. D., Gomez-Gracia, E., Martin, B. C., Steck, S. E., Kardinaal, A. F., Ringstad, J., Thamm, M. & Masaev, V., et al (1997) Lycopene and myocardial infarction risk in the EURAMIC Study. Am. J. Epidemiol. 146:618-626.
29. Sesso, H. D., Liu, S., Gaziano, J. M. & Buring, J. E. (2003) Dietary lycopene, tomato-based food products and cardiovascular disease in women. J. Nutr. 133:2336-2341.
30. Sesso, H. D., Buring, J. E., Norkus, E. P. & Gaziano, J. M. (2004) Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. Am. J. Clin. Nutr. 79:47-53.
31. Di Mascio, P., Kaiser, S. & Sies, H. (1989) Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch. Biochem. Biophys. 274:532-538.[Medline]
32. Conn, P. F., Schalch, W. & Truscott, T. G. (1991) The singlet oxygen and carotenoid interaction. J. Photochem. Photobiol. B 11:41-47.[Medline]
33. Nelsom, W. G., De Marzo, A. M. & Isaacs, W. B. (2003) Mechanisms of disease: prostate cancer. N. Engl. J. Med. 349:366-381.
34. Wang, S., DeGroff, V. L. & Clinton, S. K. (2003) Tomato and soy polyphenols reduce insulin-like growth factor-1-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J. Nutr. 133:2367-2376.
35. Pool-Zobel, B. L., Bub, A., Muller, H., Wollowski, I. & Rechkemmer, G. (1997) Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. Carcinogenesis 18:1847-1850.
36. Kucuk, O., Sarkar, F. H., Sakr, W., Djuric, Z., Pollak, M. N., Khachik, F., Li, Y. W., Banerjee, M. & Grignon, D., et al (2001) Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. 10:861-868.
37. Chen, L., Stacewicz-Sapuntzakis, M., Duncan, C., Sharifi, R., Ghosh, L., van Breemen, R., Ashton, D. & Bowen, P. E. (2001) Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J. Natl. Cancer Inst. 93:1872-1879.
38. Beecher, G. R. (1998) Nutrient content of tomatoes and tomato products. Proc. Soc. Exp. Biol. Med. 218:98-100.[Abstract]
This article has been cited by other articles:
![]() |
S. Devaraj, S. Mathur, A. Basu, H. H. Aung, V. T. Vasu, S. Meyers, and I. Jialal A Dose-Response Study on the Effects of Purified Lycopene Supplementation on Biomarkers of Oxidative Stress J. Am. Coll. Nutr., April 1, 2008; 27(2): 267 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Mills, P. W. Simon, and S. A. Tanumihardjo {beta}-Carotene from Red Carrot Maintains Vitamin A Status, but Lycopene Bioavailability Is Lower Relative to Tomato Paste in Mongolian Gerbils J. Nutr., June 1, 2007; 137(6): 1395 - 1400. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Canene-Adams, B. L. Lindshield, S. Wang, E. H. Jeffery, S. K. Clinton, and J. W. Erdman Jr. Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning R3327-H Prostate Adenocarcinomas Cancer Res., January 15, 2007; 67(2): 836 - 843. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Thompson, J. Heimendinger, A. Diker, C. O'Neill, A. Haegele, B. Meinecke, P. Wolfe, S. Sedlacek, Z. Zhu, and W. Jiang Dietary Botanical Diversity Affects the Reduction of Oxidative Biomarkers in Women due to High Vegetable and Fruit Intake J. Nutr., August 1, 2006; 136(8): 2207 - 2212. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. van der Rest, S. Danoun, A.-M. Boudet, and S. F. Rochange Down-regulation of cinnamoyl-CoA reductase in tomato (Solanum lycopersicum L.) induces dramatic changes in soluble phenolic pools J. Exp. Bot., March 1, 2006; 57(6): 1399 - 1411. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||